Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Psychiatry Res ; 272: 86-92, 2019 02.
Artigo em Inglês | MEDLINE | ID: mdl-30579187

RESUMO

Research into hallucinations typically regards them as single sensory or unimodal experiences leading to a comparative neglect of co-occurring multi-sensory hallucinations (MSH). People with psychosis who have visual hallucinations (VH) report high rates of hallucinations in other senses (auditory, olfactory, tactile). However, it is not known if this is similar to other groups who report VH. Consequently, this study explored MSH in four different patient groups who all had current VH. Archival data from standardised assessments of visual hallucinations in people with psychosis (n = 22), eye disease (ED) (n = 82), Lewy body Dementia (LBD) (n = 41), and Parkinson's disease (PD) (n = 41) determined the presence of MSH. People with psychosis and visual hallucinations reported significantly higher rates of MSH (auditory, 73%; tactile, 82%; olfactory/gustatory hallucinations, 27%) than the LBD group (auditory, 21%; tactile, 28%; olfactory/gustatory, 6%), ED (auditory, 1%; tactile, 11%; olfactory/gustatory, 0%) and PD patients (auditory, 3%; tactile, 8%; olfactory/gustatory, 3%). Regardless of diagnostic grouping, participants with MSH reported greater conviction that the VH were real, and reported greater distress. People with psychosis with VH report high rates of MSH unlike groups of older adults with VH. These between group differences in MSH prevalence have implications for clinical practice and theory.


Assuntos
Oftalmopatias/fisiopatologia , Alucinações/fisiopatologia , Doença por Corpos de Lewy/fisiopatologia , Doença de Parkinson/fisiopatologia , Transtornos Psicóticos/fisiopatologia , Percepção Visual/fisiologia , Idoso , Oftalmopatias/complicações , Feminino , Alucinações/etiologia , Humanos , Doença por Corpos de Lewy/complicações , Masculino , Pessoa de Meia-Idade , Doença de Parkinson/complicações , Transtornos Psicóticos/complicações
2.
Psychol Med ; 48(10): 1608-1615, 2018 07.
Artigo em Inglês | MEDLINE | ID: mdl-29310738

RESUMO

BACKGROUND: The longstanding association between the major histocompatibility complex (MHC) locus and schizophrenia (SZ) risk has recently been accounted for, partially, by structural variation at the complement component 4 (C4) gene. This structural variation generates varying levels of C4 RNA expression, and genetic information from the MHC region can now be used to predict C4 RNA expression in the brain. Increased predicted C4A RNA expression is associated with the risk of SZ, and C4 is reported to influence synaptic pruning in animal models. METHODS: Based on our previous studies associating MHC SZ risk variants with poorer memory performance, we tested whether increased predicted C4A RNA expression was associated with reduced memory function in a large (n = 1238) dataset of psychosis cases and healthy participants, and with altered task-dependent cortical activation in a subset of these samples. RESULTS: We observed that increased predicted C4A RNA expression predicted poorer performance on measures of memory recall (p = 0.016, corrected). Furthermore, in healthy participants, we found that increased predicted C4A RNA expression was associated with a pattern of reduced cortical activity in middle temporal cortex during a measure of visual processing (p < 0.05, corrected). CONCLUSIONS: These data suggest that the effects of C4 on cognition were observable at both a cortical and behavioural level, and may represent one mechanism by which illness risk is mediated. As such, deficits in learning and memory may represent a therapeutic target for new molecular developments aimed at altering C4's developmental role.


Assuntos
Disfunção Cognitiva/fisiopatologia , Complemento C4a/metabolismo , Complexo Principal de Histocompatibilidade/genética , Transtornos da Memória/fisiopatologia , Transtornos Psicóticos/genética , Transtornos Psicóticos/fisiopatologia , Lobo Temporal/fisiopatologia , Adulto , Disfunção Cognitiva/diagnóstico por imagem , Feminino , Neuroimagem Funcional , Expressão Gênica/genética , Humanos , Irlanda , Imageamento por Ressonância Magnética , Masculino , Transtornos da Memória/diagnóstico por imagem , Memória de Curto Prazo/fisiologia , Rememoração Mental/fisiologia , Pessoa de Meia-Idade , Transtornos Psicóticos/diagnóstico por imagem , Lobo Temporal/diagnóstico por imagem
3.
Psychol Med ; 42(6): 1119-29, 2012 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-22008511

RESUMO

BACKGROUND: Experience Sampling Methodology (ESM) is ideally suited to test the predictions, and inform the development of contemporary cognitive models of depression. Yet there has been no systematic examination of ESM in depression research. METHOD: A search of databases (PsychARTICLES, PsycINFO, AMED, Ovid Medline and CINAHL) was conducted to identify studies published within the last 25 years investigating major depressive disorder (MDD) using ESM. RESULTS: Altogether, 19 studies using ESM, or comparable methodologies, with clinically depressed individuals were identified and critically reviewed. The identified studies examined six aspects of MDD: methodological issues; positive and negative affect; cortisol secretion; antidepressant treatment; work performance; genetic risk factors. CONCLUSIONS: Despite some methodological limitations of existing studies, ESM has made a significant contribution to our current understanding of depression by consolidating existing theories, uncovering new and clinically relevant findings and identifying questions for future research. This review concludes by introducing the possibility of using ESM as an intervention tool in clinical practice and proposing that ESM could be useful for furthering knowledge of the causes of MDD.


Assuntos
Afeto , Transtorno Depressivo Maior/psicologia , Modelos Psicológicos , Projetos de Pesquisa , Antidepressivos/uso terapêutico , Ritmo Circadiano , Bases de Dados Bibliográficas , Transtorno Depressivo Maior/tratamento farmacológico , Transtorno Depressivo Maior/genética , Emprego , Predisposição Genética para Doença , Humanos , Hidrocortisona/metabolismo , Qualidade de Vida , Estresse Psicológico/psicologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...